

# Mozambique Support for Vaccine: Measles and Rubella This Decision Letter sets out the Programme Terms of a Programme

1. Country: Mozambique

2. Vaccine grant number: MOZ-MR-R-1&2

3. Date of Decision Letter: 20 September 2020

4. Date of the Partnership Framework Agreement: 06 December 2013

5. Programme title: New Vaccine Support (NVS), Measles and Rubella, 2-dose Routine

6. Vaccine type: Measles and Rubella

7. Requested product presentation and formulation of vaccine:

MR, 10 doses/vial, lyophilised

8. Programme duration: 2017-2024

9. **Programme budget (indicative):**(subject to the terms of the Partnership Framework Agreement, if applicable)

	2019-2020	2021	2022	2023	2024	2025	Total <sup>2</sup>
Programme Budget(US\$)	1,132,109	408,503	781,242	796,449	811,613	-	3,929,916

# 10. Vaccine introduction grant:

Approval				
Year Grant number Amount (US\$)				
2017	MOZ-MR-R-1ST-VIG-MOH	0		

Disbursement					
Disbursement date Amount (US\$)					
4 July 2017	933,198				
1 October 2019	(933,198)				

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>3</sup> This is the amount that Gavi has approved.



### 11. **Product switch grant:**

Not applicable

#### 12. Indicative annual amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2019-2020	2021	2022
Number of vaccine doses	-	545,500	-
Number of AD syringes	-	813,600	-
Number of re-constitution syringes	-	108,500	-
Number of safety boxes	-	10,150	-
Annual Amounts (US\$)	1,132,109	408,503	-

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

# 14. Self-procurement:

Not applicable

# 15. **Co-financing obligations:**

According to the co-financing policy, the within the group:	lls	Initial self-fina	ancing				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.							
Type of supplies to be purchased with Country funds in each year	2021	2022	2023	2024	2025		
Number of vaccine doses	441,000	1,111,000	1,132,500	1,154,000	-		
Number of AD syringes	-	-	-	-	-		
Number of re-constitution syringes	-	-	-	-	-		
Number of safety boxes	-	-	-	-	-		
Value of vaccine doses (US\$)	289,296	655,936	668,628	681,322	-		



Total co-financing payments (US\$) (including freight)	295,917	672,613	685,631	698,645	-
--	---------	---------	---------	---------	---

16.	Operational	support for	campaigns:
-----	-------------	-------------	------------

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:  • vaccine stock levels including buffer stock, by end of March;  • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.  • Countries shall report the actual switch date in the first renewal request following the actual implementation.	31 March 15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18.	Finan	cial	clarific	ations:
-----	-------	------	----------	---------

Not applicable

19. Other conditions:

Not applicable

Signed by,

On behalf of Gavi

Pascal Bijleveld Director, Country Support 24 September 2020